Hints and tips:
...Rachel McMinn, analyst at Bank of America Merrill Lynch, said: “The danger of all of these companies coming public is that a lot of them are going to fail because drug development isn’t that easy....
...Rachel McMinn of BofA Merrill Lynch Global research Rachel McMinn has been a biotech analyst at BofA-ML since 2009, at Cowen from 2007-2009, and Piper Jaffray from 2001-2007....
...Breakdowns, and eventually build-ups, in co-operation between politicians in both the eurozone and the US dominated attention for most of 2011....
International Edition